


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
NVO
Novo Nordisk A/S
$59.86
Strengths

Earnings are forecast to grow

Trading below its fair value

Upgraded on attractively valued

Investors confidence is positive
Technical Indicators

5+ Days Up
NVO Price Performance
$50.18 (+19.29%)
$56.72 (+5.54%)
$54.78 (+9.27%)
$85.19 (-29.73%)
NVO has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Investors losing confidence

Hit 52-week low

NVO overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
NVO Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
NVO Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
LLY
1081.00
+1.64%
PFE
25.27
-0.79%
LEXX
0.77
+3.20%
VKTX
31.76
-0.72%
SNY
47.60
-2.92%
AMGN
Amgen
325.54
-0.17%
NVO
Novo Nordisk A/S
59.86
+1.79%
YCBD
cbdMD Inc.
1.16
+8.41%
RYAAY
Ryanair
69.12
-0.92%
ALK
Alaska Airlines
48.67
-2.62%
What is NVO current stock price?
What are NVO stock strengths?
What is NVO Risk Level?
What is NVO market cap and volume?
What is NVO current Stock IQ?
Should I buy NVO stock right now?
Is NVO a Strong Buy right now?
What does a 'Strong Buy' rating mean for NVO?
What does a 'Strong Sell' rating mean for NVO?
What factors influence NVO's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
NVO
Novo Nordisk A/S
Current Price
$59.86
NVO Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Trading below its fair value

Upgraded on attractively valued

Investors confidence is positive
Technical Indicators

5+ Days Up
Linked to NVO
LLY
1081.00
+1.64%
PFE
25.27
-0.79%
LEXX
0.77
+3.20%
VKTX
31.76
-0.72%
SNY
47.60
-2.92%
Recently Viewed
AMGN
Amgen
325.54
-0.17%
NVO
Novo Nordisk A/S
59.86
+1.79%
YCBD
cbdMD Inc.
1.16
+8.41%
RYAAY
Ryanair
69.12
-0.92%
ALK
Alaska Airlines
48.67
-2.62%

NVO Price Performance
$50.18 (+19.29%)
$56.72 (+5.54%)
$54.78 (+9.27%)
$85.19 (-29.73%)
NVO Analysts Opinion
NVO Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
NVO Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
NVO Street Sentiment is extremely bullish and have positive views on the near-term outlook
NVO has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Investors losing confidence

Hit 52-week low

Average key support and resistance price levels
NVO Latest Analysis
Looking At Novo Nordisks Recent Unusual Options Activity. Deep-pocketed investors have adopted a bearish approach towards Novo Nordisk (NYSE:) and it'.s something market players shouldn'.t ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown but such a substantial move in NVO usually suggests something big is about to happen.We gleaned this information from our observations today when Benzinga
Today
Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing. Novo Nordisk (NVO) concluded the recent trading session at $57.34 signifying a 1.36% move from its prior days close.
Thu Jan 8, 2026
Novo Nordisk: My Top Pick For 2026.
Thu Jan 8, 2026
Veeva Expands Partnership With Novo Nordisk Through Vault CRM Adoption . (RTTNews) - Veeva Systems Inc. (VEEV) a cloud software company on Wednesday said Novo Nordisks International Operations business unit has committed to use Veeva Vault CRM expanding the companies existing partnership.
Wed Jan 7, 2026
Novo Nordisk International Operations Commits to Veeva Vault CRM. Chooses industry leading Vault CRM to empower commercial teams with next-generation CRM capabilities and agentic AI PLEASANTON Calif. Jan. 7 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Novo Nordisks International Operations business unit has committed to use...
Wed Jan 7, 2026
Warning: This Skyrocketing Stock Has a Hidden Risk. Key PointsNovo Nordisk was the first company to introduce a GLP-1 shot.
Wed Jan 7, 2026
Should Investors Be Concerned About This Pharmaceutical Giants Latest Clinical Trial?. Key PointsNovo Nordisk has released a pill version of its GLP-1 drug.
Tue Jan 6, 2026
Can the US Launch of NVOs Wegovy Pill Reignite Momentum in 2026?. Novo Nordisk shares jump after the United States launch of its FDA-approved Wegovy pill giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.
Tue Jan 6, 2026
Novo Nordisk: Wegovy Pill Is Not A Game Changer.
Tue Jan 6, 2026
Will NVOs Wegovy Pill Approval for Obesity be a Game Changer in 2026?. Novo Nordisks FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy aiming to revive momentum and reshape competition in 2026.
Mon Jan 5, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.